Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 13
CV Sciences, Inc. to Report Q1, 2026 Results on May 14, 2026 CV Sciences, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026 Tillkännagivande • Apr 17
CV Sciences, Inc., Annual General Meeting, Jun 02, 2026 CV Sciences, Inc., Annual General Meeting, Jun 02, 2026. Tillkännagivande • Mar 25
CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026 CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026 Board Change • Jan 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 11
CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025 CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025 Tillkännagivande • Aug 09
CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025 CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025 Tillkännagivande • May 10
CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025 CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025 Tillkännagivande • Apr 17
CV Sciences, Inc., Annual General Meeting, Jun 02, 2025 CV Sciences, Inc., Annual General Meeting, Jun 02, 2025. Tillkännagivande • Feb 20
CV Sciences, Inc. announced that it has received $1.2 million in funding CV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000 Tillkännagivande • Nov 22
CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million. CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions. Tillkännagivande • Nov 08
CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024 CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024 Tillkännagivande • Aug 27
CV Sciences, Inc. Launches +PlusHLTH CV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies. Reported Earnings • Aug 14
Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.008 loss in 2Q 2023) Second quarter 2024 results: US$0.003 loss per share (improved from US$0.008 loss in 2Q 2023). Revenue: US$3.95m (flat on 2Q 2023). Net loss: US$584.0k (loss narrowed 55% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 07
CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024 CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024 Tillkännagivande • Jun 08
CV Sciences, Inc. Elects Bill Mccorkle as Directors CV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors. Reported Earnings • May 16
First quarter 2024 earnings released: US$0.004 loss per share (vs US$0.038 profit in 1Q 2023) First quarter 2024 results: US$0.004 loss per share (down from US$0.038 profit in 1Q 2023). Revenue: US$4.00m (down 3.5% from 1Q 2023). Net loss: US$628.0k (down 111% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • May 10
CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024 CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024 Tillkännagivande • Apr 13
CV Sciences, Inc., Annual General Meeting, Jun 03, 2024 CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors. Tillkännagivande • Mar 26
CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews CV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives. Tillkännagivande • Mar 22
CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024 CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024 Tillkännagivande • Dec 14
CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million. CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023. Tillkännagivande • Nov 10
CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023 CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023 Tillkännagivande • Sep 06
CV Sciences, Inc. Launches Reserve Sleep Gummies CV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health. Reported Earnings • Aug 16
Second quarter 2023 earnings released: US$0.008 loss per share (vs US$0.026 loss in 2Q 2022) Second quarter 2023 results: US$0.008 loss per share (improved from US$0.026 loss in 2Q 2022). Revenue: US$3.97m (down 4.2% from 2Q 2022). Net loss: US$1.29m (loss narrowed 64% from 2Q 2022). Tillkännagivande • Aug 03
CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023 CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023 Reported Earnings • May 18
First quarter 2023 earnings released: EPS: US$0.038 (vs US$0.019 loss in 1Q 2022) First quarter 2023 results: EPS: US$0.038 (up from US$0.019 loss in 1Q 2022). Revenue: US$4.15m (down 6.7% from 1Q 2022). Net income: US$5.71m (up US$7.92m from 1Q 2022). Tillkännagivande • May 10
CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023 CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023 Reported Earnings • Mar 30
Full year 2022 earnings released: US$0.066 loss per share (vs US$0.14 loss in FY 2021) Full year 2022 results: US$0.066 loss per share (improved from US$0.14 loss in FY 2021). Revenue: US$16.2m (down 19% from FY 2021). Net loss: US$9.13m (loss narrowed 41% from FY 2021). Board Change • Mar 06
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 15
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jan 23
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 19
CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection Softgels CV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection. Tillkännagivande • Nov 09
CV Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022 CV Sciences, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 14, 2022 Tillkännagivande • Oct 27
CV Sciences, Inc. Appoints William McCorkle as Director On October 21, 2022, the Board of Directors of CV Sciences, Inc. appointed William McCorkle as a director on the Company's Board of Directors (the Board"). Pursuant to the Company's Bylaws, Mr. McCorkle shall hold office until the next election of directors by the stockholders of the Company. Mr. McCorkle shall serve as a member of the Company's Nominations and Governance Committee and Compensation Committee, and shall serve as Chair of the Audit Committee. Mr. McCorkle is an operational executive with over 30 years of experience solving problems with innovative solutions. Mr. McCorkle is experienced in managing day-to-day operations of small to large companies across multiple industries. Mr. McCorkle has held a variety of senior financial executive positions including CFO and COO of ISCA Inc., CFO, COO & Co-Founder of StemImmune Inc., CFO and COO of Genelux Corporation, and CFO and COO of Proformance Apparel Group, LLC. Mr. McCorkle received a Bachelor of Science in Accountancy from Bentley University. Mr. McCorkle's financial expertise, as well as his independence, judgment and exceptional leadership experience makes him a valuable addition to the Board. There are no arrangements or understandings between Mr. McCorkle and any other person pursuant to which Mr. McCorkle was selected as a director of the Company. Tillkännagivande • Sep 28
CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation CV Sciences, Inc. announced that CV Sciences has received preliminary approval of the proposed settlement of six shareholder derivative lawsuits pending in Nevada and California. These lawsuits alleged breach of fiduciary duty and other claims against current and former board members arising out of a tweet issued by Citron Research on August 20, 2018, suggesting that the Company misled investors by failing to disclose certain facts related to its efforts to secure patent protection for its product CVSI-007 from the United States Patent and Trademark Office ("USPTO"), which facts plaintiffs alleged made it less likely that the Company would obtain patent protection. Defendants at all times denied any wrongdoing. On May 19, 2020, the USPTO issued a patent pertaining to CVSI-007. The settlement agreement was executed by on July 28, 2022. On September 21, 2022, the District Court of Clark County, Nevada granted a motion for preliminary approval of the settlement agreement. On November 14, 2022, at 1:30 p.m., the District Court of Clark County, Nevada will hold a hearing to determine whether to grant final approval of the settlement agreement. The proposed settlement, if approved by the court, will resolve all claims asserted the defendants in these shareholder actions without any admission, concession or finding of any fault, liability or wrongdoing by the Company or any defendant. CV Sciences and the individual defendants continue to deny any wrongdoing. The proposed settlement contemplates the implementation by the Company of certain corporate reforms and payment of $275,000 in attorneys' fees to plaintiffs. The Company currently anticipates that all settlement payments will be paid through insurance, although no assurance can be provided. Tillkännagivande • Aug 16
CV Sciences, Inc. Announces Launch of PlusCBD Reserve Collection Softgels CV Sciences, Inc. announced the launch of +PlusCBD Reserve Collection Softgels to support stress relief and relaxation. The product will be available on +PlusCBD's' website on August 15, 2022. +PlusCBD Reserve Collection Softgels is the newest iteration of CV Sciences' top-selling Reserve Collection, the brand's sole THC line. Reserve Softgels are specially formulated to provide a full spectrum of cannabinoids, fostering feelings of calm and relief when consumers require intense support. Reserve Softgels feature a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), offering a manageable microdose perfect for consumers of all backgrounds and needs. +PlusCBD Reserve Collection Softgels are available in 60-count bottles. The Reserve Softgels join the +PlusCBD Reserve Collection's product lineup, featuring gummies and oils available in various flavors and potency. Rich and bold, the Reserve Collection elicits powerful feelings of calm, comfort and relief. Tillkännagivande • Aug 10
CV Sciences, Inc. to Report Q2, 2022 Results on Aug 15, 2022 CV Sciences, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 15, 2022 Tillkännagivande • Jul 28
CV Sciences, Inc. Appoints Jamie Corroon as Director On July 21, 2022, the Board of Directors of CV Sciences, Inc. appointed Dr. Jamie Corroon Jr., ND, MPH as a director on the Company's Board of Directors (the Board"). Pursuant to the Company's Bylaws, Dr. Corroon shall hold office until the next election of directors by the stockholders of the Company. From 2020-present, Dr. Corroon served on the Company's Medical Advisory Board. He is a licensed Naturopathic Doctor who advises dietary supplement and cannabis companies regarding science, regulation, and product development. Dr. Corroon is the founder of, and since 2017 has served as, the Medical Director and Principal Investigator for the Center for Medical Cannabis Education, a for-profit clinical practice and research entity. He also has served as a Research Investigator at the Helfgott Research Institute at the National University of Natural Medicine since 2017. Dr. Corroon received a Bachelor's Degree in Political Science from the University of Southern California and obtained a Master's Degree in Public Health, Epidemiology from San Diego State University. He received his Doctor of Naturopathic Medicine license from Bastyr University. Dr. Corroon is well published in peer-reviewed literature with recent publications that investigate the clinical and public health implications of the broadening acceptance of cannabis in society. Dr. Corroon's medical expertise, as well as his independence, judgment and exceptional leadership experience makes him a valuable addition to the Board. Tillkännagivande • May 13
CV Sciences, Inc. to Report Q1, 2022 Results on May 16, 2022 CV Sciences, Inc. announced that they will report Q1, 2022 results Pre-Market on May 16, 2022 Tillkännagivande • Apr 16
CV Sciences, Inc., Annual General Meeting, May 26, 2022 CV Sciences, Inc., Annual General Meeting, May 26, 2022, at 10:00 Pacific Standard Time. Agenda: To elect two directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to approve an amendment to company's Certificate of Incorporation, as amended, to increase the number of shares of capital stock authorized for issuance thereunder from 200,000,000 shares to 800,000,000 shares, and the number of shares of common stock authorized for issuance thereunder from 190,000,000 shares to 790,000,000 shares;and to discuss other matters. Tillkännagivande • Apr 03
CV Sciences, Inc. announced delayed annual 10-K filing On 04/01/2022, CV Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Reported Earnings • Apr 02
Full year 2021 earnings released: US$0.14 loss per share (vs US$0.22 loss in FY 2020) Full year 2021 results: US$0.14 loss per share (up from US$0.22 loss in FY 2020). Revenue: US$20.0m (down 18% from FY 2020). Net loss: US$15.6m (loss narrowed 30% from FY 2020). Over the next year, revenue is forecast to grow 20%, compared to a 6.9% growth forecast for the industry in the United Kingdom. Tillkännagivande • Mar 29
CV Sciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022 CV Sciences, Inc. announced that they will report Q4, 2021 results After-Market on Mar 31, 2022 Tillkännagivande • Mar 10
CV Sciences, Inc. Announces the Addition of +PlusCBD Relief Softgels to Its Wellness Line of CBD Products CV Sciences, Inc. announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature Levagen®+ PEA, the CBD-like compound shown by clinical studies to be an alternative to ibuprofen. This highly optimized trio promotes a healthy inflammatory response and provides a safe alternative in helping to manage occasional soreness. Buying Opportunity • Jan 15
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 6.6%. The fair value is estimated to be US$0.28, however is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% per annum over the last 3 years. The company became loss making over the last 3 years. Tillkännagivande • Jan 12
CV Sciences, Inc. Announces Launch of +PlusCBD Pain Relief Topicals CV Sciences, Inc. announced the launch of +PlusCBD Pain Relief topicals: four unique Over-the-Counter products formulated to pinpoint sources of minor pain and aches using active ingredients including warming camphor and cooling menthol along with premium hemp-derived CBD and other natural emollients for skin-softening effects. The +PlusCBD Pain Relief Sport Recovery Stick is crafted for athletes and fitness enthusiasts that are active and on-the-go. This topical anti-inflammatory and analgesic stick is intended to provide temporary relief related to pain and inflammation while facilitating recovery from physical activity. The 1 oz Sport Recovery Stick is available in a convenient travel size for use on the go. Another topical analgesic cream, the +PlusCBD Pain Relief Penetrating Cream, is formulated to maximize the icy-heat effects of camphor and menthol, formulated with hemp-derived CBD, to alleviate occasional pain with sore muscles and aching joints. The +PlusCBD Pain Relief Muscle Cream can provide relief to individuals managing temporary muscle pain, stiffness or soreness related to tension, stress, overuse and other minor injuries. Finally, the +PlusCBD™ Pain Relief Arthritis Cream is formulated for arthritis patients, which represent over 22% of adults in the United States. The product’s ingredients specifically target the joints to relieve arthritis-related pain and discomfort. Reported Earnings • Aug 17
Second quarter 2021 earnings released: US$0.033 loss per share (vs US$0.047 loss in 2Q 2020) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$5.13m (down 5.0% from 2Q 2020). Net loss: US$3.53m (loss narrowed 25% from 2Q 2020). Board Change • Aug 17
High number of new directors Independent Director Paul Blake was the last director to join the board, commencing their role in 2019. Reported Earnings • May 15
First quarter 2021 earnings released: US$0.03 loss per share (vs US$0.052 loss in 1Q 2020) The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: US$4.84m (down 41% from 1Q 2020). Net loss: US$3.13m (loss narrowed 39% from 1Q 2020). Tillkännagivande • May 12
CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep Gummies CV Sciences, Inc. announced the launch of PlusCBD™ Calm and Sleep: two flavorful gummies that support healthy stress responses and sleep cycles for people getting back to their normal routines. Each PlusCBD™ Calm gummy contains 10mg of CBD derived from sustainable hemp and two neurologically-active amino acids: 5-HTP and L-Theanine. Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood. L-Theanine is an amino acid found in green tea that has been extensively researched for stress management. The synergy between L-Theanine and 5-HTP, together with PlusCBD™ promotes a balanced brain chemistry, which may help consumers manage occasional anxiety that can result from life’s stressors. PlusCBD™ Sleep gummies also contain 10mg of CBD, in addition to active ingredients – including melatonin, magnolia bark and lemon balm, which work together to support a healthy circadian rhythm. Pre-clinical studies have shown that compounds found in magnolia bark extract may soothe nerves through the modulation of certain neurotransmitters, including GABA and also work with the endocannabinoid system to support relaxation. Lemon balm, which has been used as an herbal medicine around the world for decades, also contains active compounds that support the GABA neurotransmitter system, which studies have linked to promoting restful sleep. CV Sciences’ latest offerings are third-party tested and formulated by trusted experts to ensure each product contains meaningful amounts of active ingredients that are scientifically researched. PlusCBD™ Calm and Sleep gummies contain no artificial flavoring or sweeteners, making them an attractive option for those looking to support their stress response and sleep cycle without artificial additives. Both products will be available for purchase online at www.pluscbdoil.com/cbd-gummies-for-sleep-and-calm.html beginning May 11, 2021, and at retailers later this year. Reported Earnings • Mar 20
Full year 2020 earnings released: US$0.22 loss per share (vs US$0.17 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$24.4m (down 55% from FY 2019). Net loss: US$22.3m (loss widened 34% from FY 2019). Tillkännagivande • Mar 11
CV Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021 CV Sciences, Inc. announced that they will report Q4, 2020 results After-Market on Mar 18, 2021 